Scancell Holdings PLC
Company Profile
Business description
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
Contact
Sanders Road
Unit 202, Bellhouse Building
Oxford Science Park
OxfordOX4 4GD
GBRT: +44 1865582066
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
61
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,113.47 | 43.82 | -0.54% |
| DAX 40 | 23,944.08 | 174.81 | -0.72% |
| Dow JONES (US) | 47,595.62 | 73.50 | 0.15% |
| FTSE 100 | 9,717.80 | 42.26 | -0.43% |
| HKSE | 25,906.65 | 376.04 | -1.43% |
| NASDAQ | 23,793.46 | 212.31 | 0.90% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,854.53 | 32.19 | 0.47% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |